This website is intended for healthcare professionals only
Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

5 key developments that have changed oncology in 2025

Ari J Rosenberg, Rodrigo R Munhoz, Ana Tecic Vuger, Eric Lander, Yuri Yoshinami
4 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 21st 2025

Insights from the touchONCOLOGY Future Leaders 2025

The first half of 2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, EHA and many more leading conferences around the world. We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.

Neoadjuvant and adjuvant immunochemotherapy in head and neck cancers

Neoadjuvant immunochemotherapy – such as camrelizumab (with or without docetaxel, cisplatin and fluorouracil (TPF) chemotherapy) – achieved major pathological response and 2-year event-free survival rates exceeding 90% in respectable oral cavity squamous cell carcinoma. Concurrently, adding pembrolizumab before and after surgery greatly extended disease-free survival compared to standard surgery plus chemoradiotherapy.
Ari Rosenberg
University of Chicago Medicine, Chicago, IL, USA
Neoadjuvant treatments in cutaneous malignancies

Neoadjuvant immunotherapy is revolutionizing treatment for high-risk cutaneous cancers including melanoma and squamous-cell carcinomas. It boosts pathologic response rates, permits therapy personalization, reduces surgery impact and improves event-free outcomes. Ongoing trials and updated guidelines increasingly favour neoadjuvant approaches.
Rodrigo Munhoz
Oncology Center – Hospital Sírio-Libanês in São Paulo, Brazil
Breakthrough clinical trials HR+/HER2− breast cancer

Recent trials highlight potential first-line practice changes in metastatic breast cancer. DESTINY-Breast09 and ASCENT-04/KEYNOTE-D19 showed that antibody–drug conjugates (trastuzumab deruxtecan, sacituzumab govitecan) combined with targeted agents improved progression-free survival and reduced toxicity compared with chemotherapy in HER2-positive and PD-L1+ triple-negative disease. SERENA-6 demonstrated that switching from an aromatase inhibitor to camizestrant upon ESR1 mutation detection − before progression − prolonged PFS in HR+/HER2− disease. INAVO120 showed that adding inavolisib to palbociclib/fulvestrant improved survival and delayed chemotherapy in PIK3CA-mutated HR+/HER2− disease. Collectively, these findings support more personalized, mutation-driven first-line strategies.
Ana Tecic Vuger
University Hospital Centre Zagreb, Croatia
New targeted combinations for BRAF V600E-mutant metastatic colorectal cancer

Encorafenib plus cetuximab has transformed outcomes for BRAF V600E-mutant metastatic colorectal cancer, historically a difficult-to-treat subtype. Clinical trials and real-world data show improved overall survival, higher response rates and better tolerability compared to chemotherapy. In 2025, this targeted approach provides patients with a meaningful and effective therapeutic option.
Eric Lander
Minnesota Oncology – Minneapolis, MN, USA
Optimizing perioperative treatment strategies in gastrointestinal cancer

The most significant advances in gastrointestinal cancer chemotherapy have centered on optimizing perioperative treatment strategies. Firstly, the use of circulating tumour DNA (ctDNA) to guide adjuvant chemotherapy decisions in colorectal cancer has made great strides. Results from the DYNAMIC-III trial have supported a risk-adapted approach: omitting chemotherapy in ctDNA-negative patients and intensifying it in ctDNA-positive ones. This approach represents a move toward truly personalized perioperative care.

Yuri Yoshinami
National Cancer Center Hospital, Chūō, Japan

Coming soon…

What are our Future Leaders excited to hear more about for the rest of 2025?

From gene expression profiling and liquid biopsy in melanoma, to the integration of minimal residual disease monitoring using ctDNA in breast cancer and the potential of CAR-T therapy across many solid tumours — our Future Leaders will be sharing what they’re most looking forward to in the second half of the year. Stay tuned for their expert predictions and the innovations they believe could define the next wave of progress in oncology.

Learn more about the touchONCOLOGY Future Leaders 2025 here.

Opening soon!

Nominations for touchONCOLOGY Future Leaders 2026

We are excited to announce that nominations for the touchONCOLOGY Future Leaders 2026 will open soon, and we invite the oncology and haematology community to share their suggestions for exceptional individuals who are shaping the future of oncology and haematology through innovation and excellence in patient care.

Register below to hear about nominations as soon as they open!

Citation: 5 key developments that have changed oncology in 2025. touchONCOLOGY.com. August 21st, 2025.

Register now to receive the touchONCOLOGY newsletter!

Don’t miss out on hearing about our latest peer reviewed articles, expert opinions, conference news, podcasts and more.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches

Jacob N Stein, Sandra P D’Angelo

Sarcomas are a diverse group of rare muscle, bone and connective tissue tumours. Within soft-tissue sarcoma alone, there are over 70 subtypes, which demonstrate substantial heterogeneity in biology, genetics and clinical behaviour.1 Further complicating their management is the range of treatment responsiveness, with some subtypes wholly refractory to traditional chemotherapy, while others are quite responsive to […]

Advertisement

    • Related Content in Sarcoma

    Latest articles videos and clinical updates - straight to your inbox

    Close Popup